If at first you don’t succeed, narrow down the population and try again. This is what BioCardia did last month, beginning a new Phase III trial of its autologous CardiAMP cell therapy in heart failure after a previous one was stopped in the summer.
BioCardia Aims To Defy Precedent With A Cardiac Cell Therapy
Heart disease seems impervious to cell therapy approaches. Is biomarker stratification the answer?
More from Clinical Trials
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.